

a period of months to years (1). Diabetic complications similarly progress over a period of several years. Hemoglobin-AGE measurements may prove useful in the evaluation of the pharmacological efficacy of newly emerging drugs aimed at inhibiting the advanced glycosylation pathway. The demonstration of decreased Hb-AGE levels as a result of aminoguanidine therapy provides the first direct evidence of the efficacy of this drug in preventing advanced glycosylation in human subjects.

REFERENCES AND NOTES

1. M. Brownlee, A. Cerami, H. Vlassara, *N. Engl. J. Med.* **318**, 1315 (1988); F. G. Njoroge and V. M. Monnier, *Prog. Clin. Biol. Res.* **304**, 85 (1989); F. Ledl and E. Schleicher, *Angew. Chem.* **6**, 565 (1990); R. Bucala and A. Cerami, *Adv. Pharmacol.* **23**, 1 (1992).
2. R. M. Bookchin and P. M. Gallop, *Biochem. Biophys. Res. Commun.* **32**, 86 (1968); R. J. Koenig, S. H. Blobstein, A. Cerami, *J. Biol. Chem.* **252**, 2992 (1977).
3. R. J. Koenig *et al.*, *N. Engl. J. Med.* **295**, 417 (1976); M. L. Larsen, M. Horder, E. F. Morgensen, *ibid.* **323**, 1021 (1990).
4. S. L. Schneider and R. R. Kohn, *J. Clin. Invest.* **67**, 1630 (1981); R. R. Kohn, A. Cerami, V. M. Monnier, *Diabetes* **33**, 57 (1984); V. M. Monnier, R. R. Kohn, A. Cerami, *Proc. Natl. Acad. Sci. U.S.A.* **81**, 583 (1984).
5. H. Vlassara, M. Brownlee, A. Cerami, *Proc. Natl. Acad. Sci. U.S.A.* **82**, 5588 (1985).
6. C. Esposito, H. Gerlach, J. Brett, D. Stern, H. Vlassara, *J. Exp. Med.* **170**, 1387 (1989); E. Y. Skolnick *et al.*, *ibid.* **174**, 931 (1991).
7. H. Vlassara, M. Brownlee, K. R. Manogue, C. A. Dinarello, A. Pasagian, *Science* **240**, 1546 (1988); M. Kirstein *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **87**, 9010 (1990).
8. R. Bucala, K. Tracey, A. Cerami, *J. Clin. Invest.* **87**, 432 (1991); M. Hogan, A. Cerami, R. Bucala, *ibid.*, in press.
9. M. Brownlee, H. Vlassara, A. Kooney, P. Ulrich, A. Cerami, *Science* **232**, 1629 (1986).
10. K. Nichollas and T. E. Mandel, *Lab. Invest.* **60**, 486 (1989); B. S. Lewis and J. J. Harding, *Exp. Eye Res.* **50**, 463 (1990); P. R. Odetti, A. Borgoglio, A. DePascale, R. Rolandi, L. Adezati, *Diabetes* **39**, 796 (1990); T. Soulis-Liparota, M. Cooper, D. Papazoglou, B. Clarke, G. Jerums, *ibid.* **40**, 1328 (1991); E. N. Ellis and B. H. Good, *Metabolism* **40**, 1016 (1991); H. P. Hammes, S. Martin, K. Federlin, K. Geisen, M. Brownlee, *Proc. Natl. Acad. Sci. U.S.A.* **88**, 11555 (1991); S. Yagihashi, M. Kamijo, M. Baba, N. Yagihashi, K. Nagai, *Diabetes* **41**, 47 (1992).
11. Z. Makita, H. Vlassara, A. Cerami, R. Bucala, *J. Biol. Chem.* **267**, 5133 (1992).
12. Five milliliters of whole blood was collected into heparinized tubes. We prepared hemoglobin for immunoassay following an established procedure [Z. Makita *et al.*, *Diabetologia* **34**, 40 (1991)]. We hemolyzed and delipidated washed red cell pellets by resuspending cells in 3 ml of distilled H₂O and 2 ml of toluene. After vortexing, the insoluble material was pelleted by centrifugation at 3000g for 30 min. Hemolysate (100 μ l) was then added to 3 ml of H₂O. This was followed by the addition of 1 ml of ice-cold 24% trichloroacetic acid. After mixing and incubation on ice for 15 min, precipitated hemoglobin was collected by centrifugation at 3000g for 45 min. The supernatant was discarded, and the pellet was redissolved in 0.15 ml of 1 N NaOH. Three-hundred microliters of 0.3 M KPO₄ buffer (pH 7.4) then was added, and tenfold dilutions (range 1:2 to 1:2000) were subjected to competitive ELISA as described (11). Competitive immunoreactivity was expressed relative to a synthetic AGE-albumin standard [1 AGE unit = 1 μ g of AGE-albumin (11)]. Hemoglobin concentration was determined with the Lowry reagent with the use of purified bovine serum albumin as the standard [O. Lowry, N. J. Rosebrough, A. L. Farr, R. J. Randall, *J. Biol. Chem.* **193**, 265 (1951)].
13. S. Pongor, P. C. Ulrich, F. A. Bencsath, A. Cerami, *Proc. Natl. Acad. Sci. U.S.A.* **81**, 2684 (1984).
14. F. G. Njoroge, A. A. Fernandes, V. M. Monnier, *J. Biol. Chem.* **263**, 10646 (1988).
15. Informed consent was obtained from 18 diabetic patients who received aminoguanidine at an average daily dose of 1200 mg. Twelve patients had type I diabetes, and six patients had type II diabetes. The mean age was 45.7 years, and the mean duration of diabetes was 20.4 years.
16. R. Shapiro, M. J. McManus, C. Zalut, H. F. Bunn, *J. Biol. Chem.* **255**, 3120 (1980).
17. D. R. Sell and V. M. Monnier, *J. Clin. Invest.* **85**, 380 (1990); Z. Makita *et al.*, *N. Engl. J. Med.* **325**, 836 (1991).
18. C. M. Peterson and B. Formby, *Diabetes Annu.* **1**, 178 (1985).
19. Z. Makita *et al.*, data not shown.
20. We are grateful to M. Yamin and K. Manogue for helpful discussions. The expert technical assistance of H. Fuh and E. Dumaguig is acknowledged. Supported by the Brookdale Foundation and NIH grant DK19655-15.

13 May 1992; accepted 4 August 1992

Negative Selection of Precursor Thymocytes Before Their Differentiation into CD4⁺CD8⁺ Cells

Yousuke Takahama, Elizabeth W. Shores, Alfred Singer*

Thymic selection of the developing T cell repertoire is thought to occur at the CD4⁺CD8⁺ stage of differentiation and to be determined by the specificity of the T cell receptors (TCRs) that CD4⁺CD8⁺ thymocytes express. However, TCR signals can inhibit the differentiation of precursor thymocytes into CD4⁺CD8⁺ cells, which suggests that selection might occur earlier than thought. Indeed, in a negatively selecting male thymus, CD4⁺CD8^{lo} precursor thymocytes that express a transgenic TCR to male antigen are developmentally arrested as a consequence of antigen encounter and fail to become CD4⁺CD8⁺. Thus, negative selection can occur before the CD4⁺CD8⁺ stage of differentiation.

T cell differentiation in the thymus consists of an ordered sequence of developmental steps that is influenced by the specificity of the TCR that individual thymocytes express (1–4). TCR-specific selection events are thought to act on thymocytes at the CD4⁺CD8⁺ stage of differentiation, selecting individual thymocytes for either deletion or further differentiation (1–8). CD4⁺CD8⁺ thymocytes appear to be the focus of thymic selection because their numbers are depleted in TCR-transgenic mice from negatively selecting mouse strains (3, 4, 6, 7) presumably because CD4⁺CD8⁺ transgenic thymocytes encounter antigen and are deleted. However, it is also possible that CD4⁺CD8⁺ transgenic thymocytes are low in number in negatively selecting strains because they fail to develop in these mice. To assess this latter possibility, we have examined the effect of TCR-mediated signals on the generation of CD4⁺CD8⁺ thymocytes from their immediate precursor cells in both normal mice and mice that express transgenic TCR $\alpha\beta$ molecules (Tg-TCR $\alpha\beta$) specific for the antigenic complex created by the male antigen H-Y and H-2D^b (D^b).

The immediate precursors of CD4⁺CD8⁺ thymocytes are CD4⁺CD8^{lo}

thymocytes that constitute all the CD4⁺CD8⁺ cells present in the fetal thymus because mature CD4⁺CD8⁺ thymocytes do not appear until after birth (1, 9). To further enrich fetal thymocyte populations from both normal and Tg-TCR $\alpha\beta$ mice for precursor cells, we eliminated thymocytes that had already become CD4⁺CD8⁺ in vivo by treatment with a monoclonal antibody (MAb) to CD4 and complement (C) (Fig. 1). Such CD4⁺ fetal thymocyte populations consisted of two immature subsets that were distinguishable by their expression of CD8, being either CD4⁺CD8^{lo} or CD4⁺CD8⁺ (Fig. 1). Placement of such CD4⁺ fetal thymocytes into suspension culture resulted in the generation of CD4⁺CD8⁺ cells (Fig. 1), all of which were derived from CD4⁺CD8^{lo} precursor cells. The derivation of these cells was determined by experiments in which precursor thymocytes were physically separated by electronic cell sorting into CD4⁺CD8^{lo} and CD4⁺CD8⁺ cells (Fig. 1); CD4⁺CD8^{lo} thymocytes did not undergo any detectable phenotypic change in culture (Fig. 1). Thus, precursors for CD4⁺CD8⁺ thymocytes could be uniquely identified among CD4⁺ fetal thymocytes as CD8^{lo} cells and could be induced to further differentiate into CD4⁺CD8⁺ thymocytes by placement in suspension culture.

Studies with adult rat thymocytes have suggested that differentiation of cells expressing no CD4 and relatively little CD8

Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

*To whom correspondence should be addressed.

(CD4⁻CD8^{lo} cells) into CD4⁺CD8⁺ thymocytes can be inhibited by antibody-induced TCR cross-linking (10), but it has been debated whether CD4⁻CD8^{lo} precursor thymocytes even express the TCRs on their surface (9–11). However, small amounts of the TCRs were detected on CD4⁻CD8^{lo} murine precursor thymocytes from normal fetal mice by direct staining with fluorescein isothiocyanate (FITC)-labeled MAb to TCR β , which was specifically inhibited by MAb to TCR β but not by tenfold higher concentrations of MAb to CD3 ϵ (Fig. 2A). We then examined whether antibody-induced TCR signals inhibited the differentiation of murine CD4⁻CD8^{lo} fetal precursor thymocytes. Suspension culture of CD4⁻CD8^{lo} fetal thymocytes resulted in the appearance of surface CD4 molecules; this appearance was quantitatively inhibited by plate-bound MAb to TCR β (Fig. 2B). MAb to TCR β was significantly more inhibitory in plate-bound form than in soluble form, which indicates a requirement for TCR cross-linking (Fig. 2B). The inhibitory effect of

MAb to TCR β was specific because MAb to TCR δ had no effect. Finally, TCR cross-linking induced by plate-bound MAb to TCR β inhibited the differentiation of CD4⁻CD8^{lo} precursor thymocytes into CD4⁺CD8⁺ cells and did not simply induce a redistribution of CD4 molecules because the cross-linking also inhibited the appearance of CD4 mRNA (Fig. 2C).

To address the possibility that antigen engagement of TCR complexes might clonally regulate the differentiation of CD4⁻CD8^{lo} precursor cells into CD4⁺CD8⁺ thymocytes, we analyzed precursor thymocytes that expressed the TCRs with a defined antigen specificity, namely D^b+H-Y. Fetal mice that expressed the anti-male TCR $\alpha\beta$ transgene were obtained from normal C57BL/6 (*H-2^b*) pregnant females (B6) that had been impregnated by a homozygous Tg-TCR $\alpha\beta$ male and so were themselves heterozygous for the TCR $\alpha\beta$ transgene. Approximately 50% of CD4⁻CD8^{lo} cells from

H-2^b Tg-TCR $\alpha\beta$ mice became CD4⁺ during 12-hour suspension cultures, and their differentiation into CD4⁺CD8⁺ thymocytes was blocked by MAbs that bind and cross-link the transgenic TCR (MAbs to TCR β and to TCR-V β 8) (Fig. 3). The differentiation of Tg-TCR $\alpha\beta$ precursor cells was also inhibited by antigen-presenting cells (APCs) from male *H-2^b* nude mice that express the antigenic ligand (D^b+H-Y) for the TCR transgene but not by APCs from female *H-2^b* nude mice (Fig. 3). Thus, antigen-induced developmental arrest can occur before the CD4⁺CD8⁺ stage of development.

If antigen-induced developmental arrest of CD4⁻CD8^{lo} Tg-TCR $\alpha\beta$ thymocytes occurred in vivo, CD4⁻CD8^{lo} precursor thymocytes from negatively selecting Tg-TCR $\alpha\beta$ male mice should be arrested as a consequence of having encountered the male antigen in vivo. Consistent with this prediction, a significant fraction of pooled





Fig. 1. Fetal CD4⁻CD8⁺ thymocytes become CD4⁺CD8⁺ cells in suspension culture (14). Thymocytes were obtained from normal C57BL/6 (B6; *H-2^b*) or Tg-TCR $\alpha\beta$ mice on day 19 of gestation. Where indicated, thymocytes were further treated with MAb to CD4 and C to remove cells that had already become CD4⁺CD8⁺ cells in vivo. The indicated cell populations were then placed in single-cell suspension culture for 12 hours. Cell populations were analyzed by two-color flow cytometry for CD4/CD8 expression. As indicated in the lower panels, day 19 fetal thymocytes treated with MAb to CD4 and C were also electronically sorted into CD8⁺ and CD8⁻ cell populations and then cultured in single-cell suspension for 12 hours. Numbers in each box of contour diagrams indicate the frequency of cells in that box. After the 12-hour culture, CD4⁺CD8⁺ cells were evident in all groups except those from CD4⁻CD8⁻ cells.

Fig. 2. TCRs on CD4⁻CD8⁺ precursor thymocytes from normal fetal mice could generate signals that inhibit differentiation into CD4⁺CD8⁺ cells. (A) Specificity of TCR β staining of fetal CD4⁻CD8⁺ thymocytes from normal mice. CD4⁻ day 19 fetal B6 thymocytes were analyzed for TCR β and CD8 staining by two-color flow cytometry (14). Single-color histograms of TCR β staining are displayed on electronically gated CD8⁺ cells. TCR expression was determined by staining with FITC-labeled MAb to TCR β (H57). The ability of intact or F(ab')₂ fragments (15) of unlabeled MAbs to block staining by MAb to TCR β was determined by incubating cells with blocking antibody or F(ab')₂ fragments for 30 min at 4°C before staining with either MAb to TCR β (solid lines) or control MAb (dashed lines). (B) Effects of TCR signals on surface CD4 expression by normal CD4⁻CD8⁺ precursor thymocytes in suspension culture. CD4⁻ thymocytes from day 19 fetal B6 mice were cultured for 16 hours with MAbs to TCR and assessed for CD4 and CD8 expression by two-color flow cytometry (14). MAbs to TCR β and TCR δ were H57-597 (15) and GL3 (16), respectively. Plate-bound MAbs (xH57 and xGL3) were immobilized at 50 μ g/ml, and soluble MAbs (H57 and GL3) were added at 50 μ g/ml. CD4 fluorescence intensity on electronically gated CD8⁺ cells was quantitated in linear fluorescence units (17). Percent inhibition of CD4 fluorescence relative to groups cultured in medium alone was also calculated for each experimental group (17) and is shown above each bar. (C) Effects of TCR cross-linking on steady-state mRNA in cultured CD4⁻ fetal thymocytes from normal mice. CD4⁻ thymocytes from day 19 fetal B6 mice were cultured for 6 hours in the absence or presence of plate-bound MAb to TCR β (xTCR β). Total cellular RNA (5 μ g) from the indicated cells were analyzed by Northern (RNA) blot hybridization with the indicated probes (18). Numbers under each lane indicate relative intensities of bands as determined by densitometry. GAPDH is a housekeeping enzyme that was used as an internal standard for the relative amounts of RNA loaded in each lane.



CD4⁻CD8^{lo} fetal thymocytes from unsexed *H-2^b* Tg-TCR $\alpha\beta$ fetal mice did not differentiate in suspension culture into CD4⁺CD8⁺ cells, whereas essentially all CD4⁻CD8^{lo} precursor thymocytes from normal *H-2^b* mice did differentiate into CD4⁺CD8⁺ cells (Figs. 1 and 3). Consequently, we separately assessed the ability of CD4⁻CD8^{lo} precursor thymocytes from male and female *H-2^b* transgenic fetuses to differentiate into CD4⁺CD8⁺ cells in vitro (Fig. 4A). Virtually all precursor thymocytes from *H-2^b* female transgenic mice and unsexed *H-2^d* transgenic mice (neither of which expressed the D^b+H-Y antigenic ligand) became CD4⁺CD8⁺ in culture (Fig. 4A). In contrast, most precursor thymocytes from *H-2^b* male transgenic mice (which expressed the D^b+H-Y antigenic ligand) did not become CD4⁺CD8⁺ in culture (Fig. 4A), which indicates that they had lost their ability to differentiate in vitro into CD4⁺CD8⁺ cells. The few precursor thymocytes from male transgenic mice whose developmental capacity had not been arrested may represent cells that had not yet encountered antigen.




Fig. 3. Generation of CD4⁺CD8⁺ cells from Tg-TCR $\alpha\beta$ fetal CD4⁻CD8⁺ thymocytes in culture is inhibited by TCR cross-linking and by antigen. CD4⁻ thymocytes from day 19 *H-2^b* Tg-TCR $\alpha\beta$ fetal mice were cultured for 12 hours in medium or in the presence of plate-bound MAbs or APCs as indicated (19). Fluorescence profiles of CD8⁺-gated cells stained with MAb to CD4 (open solid lines) and control MAb (shaded dashed lines) are shown. At the end of culture, cell recoveries were >90% in all groups.


To confirm that in vivo exposure to the male antigen affected Tg-TCR $\alpha\beta$ thymocytes at the CD4⁻CD8^{lo} precursor stage of differentiation, we examined CD5 expression on precursor thymocytes from normal and transgenic fetal mice because CD5 expression increases as thymocytes differentiate and undergo thymic selection events (1). All CD4⁻CD8^{lo} fetal thymocytes from normal mice were CD5^{lo} but increased their expression of CD5 to intermediate levels (CD5^{int}) after activation by phorbol 12-myristate 13-acetate (PMA), which activates protein kinase C and mimics many TCR signals (Fig. 4B). CD4⁻CD8^{lo} fetal thymocytes from pools of unsexed *H-2^d* Tg-TCR $\alpha\beta$ fetal mice were similarly CD5^{lo} (Fig. 4B). In contrast, CD4⁻CD8^{lo} fetal thymocytes from pools of unsexed *H-2^b* Tg-TCR $\alpha\beta$ fetal mice contained a subpopulation of CD5^{int} cells in the absence of any intentional stimulation (Fig. 4B). CD4⁻CD8^{lo} fetal thymocytes from *H-2^b* Tg-TCR $\alpha\beta$ male and female mice differed in their CD5 expression, with most Tg-TCR $\alpha\beta$ male mice being CD5^{int}, which indicates that they have already encountered antigen in vivo (Fig. 4B). Although they were CD5^{int}, the CD4⁻CD8^{lo} thymocytes from Tg-TCR $\alpha\beta$ male mice were not CD4⁺CD8⁺ mature cells because they remained phenotypically immature cells by other developmental markers; they were heat-stable antigen^{hi} and intercellular adhesion molecule (ICAM)-1^{hi} (12). Thus, CD4⁻CD8^{lo} precursor thymocytes in Tg-TCR $\alpha\beta$ male mice encounter the male antigen in the thymus and, as a result, are unable to further differentiate into CD4⁺CD8⁺ cells.

Inhibition by antigen of the differentiation of CD4⁻CD8^{lo} precursor cells into

CD4⁺CD8⁺ thymocytes is a mechanism of negative selection that occurs earlier than other described selection events that act on CD4⁺CD8⁺ thymocytes (2–8) or more mature cells (13). Because most CD4⁻CD8^{lo} precursor thymocytes from negatively selecting mice could not differentiate into CD4⁺CD8⁺ cells, antigen-induced developmental blockade of precursor thymocytes is probably the main cause of the low number of CD4⁺CD8⁺ thymocytes in negatively selecting *H-2^b* Tg-TCR $\alpha\beta$ male mice. However, the concept of developmental blockade of precursor thymocytes is complementary to, and not mutually exclusive of, the concept of subsequent antigen-induced deletion of CD4⁺CD8⁺ thymocytes in these animals. Antigen-induced TCR signals can be generated only in precursor thymocytes with TCRs that engage antigen in the absence of CD4 and in the presence of little CD8. Thus, antigen-induced developmental blockade of precursor thymocytes might be expected to primarily affect thymocytes that express high-affinity TCRs with major histocompatibility complex (MHC) class I restriction specificities. In fact, negatively selecting thymuses of transgenic mice that express different TCR transgenes restricted by MHC class I determinants are all depleted of early TCR^{lo}CD4⁺CD8⁺ cells (3, 4, 6, 7), consistent with antigen-induced developmental arrest of precursor thymocytes being the primary mechanism of negative selection in these experimental animals.

The ultimate fate of antigen-stimulated CD4⁻CD8^{lo} precursor thymocytes is unclear. These thymocytes are probably not long-lived end-stage cells because they do not accumulate in negatively selecting mice. However, they do not appear to

Fig. 4. Most fetal precursor thymocytes from *H-2^b* Tg-TCR $\alpha\beta$ male mice cannot become CD4⁺CD8⁺. (A) The inability of fetal CD4⁻CD8⁺ thymocytes from *H-2^b* male Tg-TCR $\alpha\beta$ mice to generate CD4⁺CD8⁺ cells in culture. CD4⁻ day 19 fetal thymocytes from normal B6 mice, sexed *H-2^b* Tg-TCR $\alpha\beta$ mice (20), and unsexed *H-2^d* Tg-TCR $\alpha\beta$ mice were cultured for 14 hours. Fluorescence profiles of CD8⁺-gated cells stained with MAb to CD4 (open solid lines) and control MAb (shaded dashed lines) were obtained before culture and after 14 hours of culture. Fluorescence profiles of normal and transgenic thymocytes before culture were essentially identical. (B) Increased CD5 expression on CD4⁻CD8^{lo} precursor thymocytes from *H-2^b* male Tg-TCR $\alpha\beta$ mice (21). Top panel shows CD5 expression in freshly prepared CD4⁻CD8⁺ day 19 fetal thymocytes from unsexed *H-2^b* Tg-TCR $\alpha\beta$ mice (shaded curve), unsexed *H-2^d* Tg-TCR $\alpha\beta$ mice (stippled curve), or normal B6 mice (dashed lines). CD5 expression by CD4⁻CD8^{lo} fetal B6 thymocytes cultured for 12 hours with PMA is also shown (dashed line). PMA-stimulated cells remained CD4⁻CD8^{lo} (12). Bottom panel shows CD5 expression in freshly prepared CD4⁻CD8⁺ day 19 fetal thymocytes from *H-2^b* male and *H-2^b* female Tg-TCR $\alpha\beta$ mice. Fluorescence profiles of CD8⁺-gated cells stained with MAb to CD5 (open solid lines) and control MAb (shaded dashed lines) are shown.



undergo programmed cell death because they do not fragment their DNA (12). Rather, antigen-stimulated CD4⁺CD8^{lo} precursor thymocytes may become CD4⁺CD8⁺TCR $\alpha\beta$ ⁺ thymocytes, which would explain the disproportionate appearance of such thymocytes in Tg-TCR $\alpha\beta$ male mice (3, 4).

Our data show that TCR signals generated in CD4⁺CD8^{lo} precursor thymocytes can clonally regulate their differentiation into CD4⁺CD8⁺ cells. Consequently, the TCR repertoire expressed by early CD4⁺CD8⁺ thymocytes may already reflect the influence of intrathymic selection pressures.

REFERENCES AND NOTES

- B. J. Fowlkes and D. M. Pardoll, *Adv. Immunol.* **44**, 207 (1989).
- J. W. Kappler, N. Roehm, P. C. Marrack, *Cell* **49**, 273 (1987); B. J. Fowlkes, R. H. Schwartz, D. M. Pardoll, *Nature* **334**, 620 (1988).
- H. S. Teh *et al.*, *Nature* **335**, 229 (1988).
- H. von Boehmer, *Annu. Rev. Immunol.* **8**, 531 (1990).
- W. Swat, L. Ignatowicz, H. von Boehmer, P. Kisielow, *Nature* **351**, 150 (1991).
- W. C. Sha *et al.*, *ibid.* **336**, 73 (1988).
- H. Pircher, K. Bürki, R. Lang, H. Hengartner, R. M. Zinkernagel, *ibid.* **342**, 559 (1989).
- L. J. Berg, B. Fazekas de St. Groth, A. M. Pullen, M. M. Davis, *ibid.* **340**, 559 (1989); L. J. Berg *et al.*, *Cell* **58**, 1035 (1989); K. M. Murphy, A. B. Heimberger, D. Y. Loh, *Science* **250**, 1720 (1990); N. J. Vasquez, J. Kaye, S. M. Hedrick, *J. Exp. Med.* **175**, 1307 (1992).
- D. J. Paterson and A. F. Williams, *J. Exp. Med.* **166**, 1603 (1987); H. R. MacDonald, R. C. Budd, R. C. Howe, *Eur. J. Immunol.* **18**, 519 (1988); K. Shortman, A. Wilson, M. Egerton, M. Pearce, R. Scollay, *Cell. Immunol.* **113**, 462 (1988).
- T. Hunig, *Eur. J. Immunol.* **18**, 2089 (1988).
- J. Nikolic-Zugic and M. W. Moore, *ibid.* **19**, 1957 (1989); H. T. Petrie *et al.*, *J. Exp. Med.* **172**, 1583 (1990).
- Y. Takahama and A. Singer, unpublished results.
- C. Benoist and D. Mathis, *Cell* **58**, 1027 (1989); H. R. MacDonald and R. K. Lees, *Nature* **343**, 642 (1990); L. A. Jones, L. T. Chin, D. L. Longo, A. M. Kruisbeek, *Science* **250**, 1726 (1990); B. Rocha and H. von Boehmer, *ibid.* **251**, 1225 (1991).
- Tg-TCR $\alpha\beta$ mice express the anti-male TCR and were originally developed by von Boehmer and colleagues (4). The H-2^b and H-2^d Tg-TCR $\alpha\beta$ fetuses were obtained from C57BL/6 and BALB/c females, respectively, impregnated by a homozygous Tg-TCR $\alpha\beta$ male mouse. Thymocytes from day 19 fetal mice were treated with RL172 MAb to CD4 [R. Ceredig, J. W. Lowenthal, M. Nabholz, H. R. MacDonald, *Nature* **314**, 98 (1985)] plus C and then separated by lympholyte-M (Cederlane Laboratories, Hornby, Ontario, Canada) centrifugation. These CD4⁺ cells were further stained with MAb to CD8 (53-6-72; Becton-Dickinson, San Jose, CA) and sorted into CD8⁺ (CD4⁺CD8⁺) and CD8⁺ (CD4⁺CD8⁺) cells by a FACStar Plus cell sorter (Becton-Dickinson). Cells were cultured at 0.5 $\times$ 10⁶ to 2 $\times$ 10⁶ cells per milliliter in 24-well Costar plates in RPMI-1640 medium supplemented with 10% fetal bovine serum and 5 $\times$ 10⁻⁵ M 2-mercaptoethanol at 37°C in a humidified atmosphere with 5% CO₂. Cultured cells were stained with MAb to CD4 conjugated to FITC (Rm4-5; Pharmingen, San Diego, CA) and MAb to CD8 (53-6-72) conjugated to biotin and then with Texas red linked to avidin. The two MAbs to CD4, RL172 and Rm4-5, bind to different CD4 epitopes and do not compete with one another. All staining was performed in the presence of unlabeled MAb to the Fc receptor to block Fc receptor-mediated binding.
- MAb to the TCR β (H57-597) [R. T. Kubo, W. Born, J. Kappler, P. Marrack, M. Pigeon, *J. Immunol.* **142**, 2736 (1989)] was digested with immobilized pepsin (Pierce, Rockford, IL), and the purity of the resulting F(ab')₂ fragment was ascertained by SDS-polyacrylamide gel electrophoresis. Immunoglobulin G (IgG) fraction of MAb to CD3 ϵ (145-2C11) [O. Leo, M. Foo, D. H. Sachs, L. E. Samelson, J. A. Bluestone, *Proc. Natl. Acad. Sci. U.S.A.* **84**, 1374 (1987)] was also used (2C11-IgG).
- T. Goodman and L. LeFrancis, *J. Exp. Med.* **170**, 1569 (1989).
- Fluorescence units (FU) are median intensity of CD4 staining minus median intensity of control MAb Leu4 staining. We calculated median intensity by converting median log channel number to linear units with an empirically derived calibration curve for each logarithmic amplifier used. Percent inhibition of CD4 FU was calculated as 100 $\times$ (FU of cultured cells with medium alone - FU of experimental group)/(FU of cultured cells with medium alone - FU of uncultured precursor cells).
- Total cellular RNA was prepared from the indicated cell populations, and equal amounts of RNA (5 μ g) were denatured, separated by electrophoresis on agarose gels, and transferred to nylon membranes as described [T. Maniatis, E. F. Fritsch, J. Sambrook, *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1982)]. Blots were hybridized with a 2.1-kb Eco RI fragment of CD4 cDNA [D. R. Littman and S. N. Gettner, *Nature* **325**, 453 (1987)] or 1.3-kb Pst I fragment of rat glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA [P. Fort *et al.*, *Nucleic Acids Res.* **13**, 1431 (1985)] that had been labeled with ³²P by the random primer method.
- CD4⁺ day 19 fetal thymocytes from pools of unsexed H-2^b Tg-TCR $\alpha\beta$ mice were prepared, cultured, and stained (14). MAb with indicated specificity [50 μ g/ml; either H57-597 (H57) for MAb to TCR β or MR5-2 (Pharmingen) for MAb to V β 8] was coated onto the culture wells. Plastic-adherent cells (APCs) were prepared from spleen cells of T cell-deficient B10-nu/nu mice (5). Where indicated, thymocytes (0.5 $\times$ 10⁶ cells per milliliter) were cocultured with APCs (0.4 $\times$ 10⁶ cells per milliliter) in 24-well Costar plates.
- Fetal Tg-TCR $\alpha\beta$ mice on day 19 of gestation were sexed according to their internal genital organs [K. Theiler, *The House Mouse: Atlas of Embryonic Development* (Springer-Verlag, New York, 1989)].
- CD4⁺ day 19 fetal thymocytes were stained with FITC-conjugated MAb to CD5 (53-7-3; Becton-Dickinson) and biotinylated MAb to CD8 and then TR-avidin was added. CD5 expression was analyzed on electronically CD8⁺ gated cells. Where indicated, CD4⁺ day 19 fetal B6 thymocytes were cultured for 12 hours with PMA (100 ng/ml; Sigma).
- We thank H. von Boehmer and M. Steinmetz for making their TCR transgenic mouse strain available to the scientific community; B. J. Fowlkes for providing a homozygous transgenic male breeder mouse; M. Sheard for assistance in flow cytometry and cell sorting; M. Kuehn and L. Lowe for helping in the sex diagnosis of fetal mice; and J. A. Berzofsky, R. J. Hodes, and D. S. Singer for critically reading the manuscript.

5 June 1992; accepted 20 August 1992

Flow-Dependent Cytosolic Acidification of Vascular Endothelial Cells

Roy C. Ziegelstein, Linda Cheng, Maurizio C. Capogrossi*

Hemodynamic shear stress affects endothelial cell structure and function, but little is known about the signal transduction mechanisms involved in these processes. The effect of laminar shear stress on cytosolic pH (pH_i) was examined in rat aortic endothelial cells cultured in glass capillary tubes. Shear stress forces led to a rapid decrease in pH_i (maximal effect 0.09 pH unit at 13.4 dynes per square centimeter). Removal of specific ions or addition of exchange inhibitors suggests that in vascular endothelial cells shear stress forces activate both an alkali extruder, sodium ion-independent chloride-bicarbonate ion exchange, and an acid extruder, sodium-hydrogen ion exchange; the net effect in physiologic buffer with the bicarbonate ion is a decrease in pH_i.

Shear stress forces modulate several vascular endothelial cell functions (1), but the signal transduction mechanisms involved in these processes have not been fully elucidated. Because shear stress leads to enhanced phosphoinositide turnover (2) and membrane hyperpolarization (3), both of which may influence cytosolic pH (pH_i) regulation, pH_i could provide a signal transduction mechanism in response to changes in flow. In addition, shear stress-induced changes in cytoskeletal organization or in

agonist availability to the cell membrane might affect pH_i (4). To test the hypothesis that shear stress forces affect endothelial pH_i, we examined the effect of laminar flow on endothelial cells from the rat aorta cultured in glass capillary tubes (5).

When endothelial cells in glass capillaries were exposed to a HCO₃⁻-buffered solution equilibrated with 5% CO₂, the increase in laminar shear stress forces (6) caused a rapid and reversible decrease in pH_i (7) (Fig. 1). The threshold for this effect was below 0.5 dyne cm⁻², and it saturated between 6.7 and 13.4 dyne cm⁻² (Fig. 1A). In a HCO₃⁻ buffer, exposure to 13.4 dyne cm⁻² for 2 to 5 min resulted in an intracellular acidification of 0.09 $\pm$ 0.01 pH units ($n = 79$; $P < 0.0001$). A similar

Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, and Johns Hopkins University, Division of Cardiology, Baltimore, MD 21205.

*To whom correspondence should be addressed.